Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | F10 | P00742 | 2/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | FABP1 | P07148 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737053 | 0.90 | MEN1 (0.60) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL9938318 | 0.89 | MEN1 (0.70) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL1989713 | 0.89 | KMT2A (0.62) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL9170741 | 0.87 | MEN1 (0.58) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL6829100 | 0.87 | LMNA (0.59) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL5465044 | 0.87 | MAPT (0.61) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL930388 | 0.85 | AKR1C3 (0.70) | KMT2ANPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL9937715 | 0.85 | TDP1 (0.63) | MEN1KMT2AMAPTL3MBTL1TDP1 | |
| SCHEMBL8955466 | 0.84 | MEN1 (0.57) | MEN1KMT2AMAPTL3MBTL1TDP1 | |
| SCHEMBL9938937 | 0.84 | SMN1; SMN2 (0.59) | MEN1KMT2AMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120183660-A1 | ISOMANNIDE DERIVATIVES AND THEIR USE AS TASTANTS | SENOMYX, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2448944-A2 | ISOMANNIDE DERIVATIVES AND THEIR USE AS TASTANTS | Senomyx, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002871-A2 | ISOMANNIDE DERIVATIVES AND THEIR USE AS TASTANTS | SENOMYX, INC (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120183660-A1 | ISOMANNIDE DERIVATIVES AND THEIR USE AS TASTANTS | TAS2R41, TAS2R42, TAS2R40 | MEN1 3312/4885KMT2A 3094/4885MAPT 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.